- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01530997
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
Phase II Study of De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80907
- Penrose Cancer Center
-
-
Florida
-
Gainesville, Florida, United States, 32610-0385
- University of Florida, Department of Radiation Oncology
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill, Department of Radiation Oncology
-
Raleigh, North Carolina, United States, 27607
- Rex Healthcare
-
Raleigh, North Carolina, United States, 27614
- Rex Cancer Center of Wakefield
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥ 18 years of age
- T0-3, N0 to N2c, M0 squamous cell carcinoma of the oropharynx
- Biopsy proven squamous cell carcinoma that is HPV and/or p16 positive
- ≤ 10 pack-years smoking history or > 5 years of abstinence from smoking
- History/physical examination within 8 weeks prior to registration
- Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration.
- The Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Complete Blood Count (CBC)/differential obtained within 4 weeks prior to registration, with adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl.
- Adequate renal and hepatic function within 4 weeks prior to registration, defined as follows: Serum creatinine < 2.0 mg/dl; Total bilirubin < 2 x the institutional upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN.
- Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential.
- Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment.
- Patients must be deemed able to comply with the treatment plan and follow-up schedule.
- Patients must provide study specific informed consent prior to study entry.
Exclusion Criteria:
- Prior history of radiation therapy to the head and neck
- Prior history of head and neck cancer.
- Severe, active co-morbidity, defined as follows: Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months; Transmural myocardial infarction within the last 6 months; Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; Note, however, coagulation parameters are not required for entry into this protocol; Pre-existing ≥ grade 2 neuropathy; Prior organ transplant.
- Known HIV positive
- Significant pre-existing hearing loss, as defined by the patient or treating physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: De-escalated Radiation and Chemotherapy
Patients will receive 54 to 60 Gy of Intensity Modulated Radiotherapy (IMRT) with concurrent weekly intravenous cisplatin (30 mg/m2).
Diagnostic imaging (CT and/or MRI) will be obtained 4 to 8 weeks after completion of CRT to assess response.
All patients will have surgical resection of any clinically apparent residual primary tumor or biopsy of the primary site if there is no evidence of residual tumor and will undergo a limited neck dissection to encompass at least those nodal level(s) that were positive pre-treatment, 4 to 14 weeks after CRT.
|
All patients will receive IMRT.
Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV).
The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy.
The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively.
The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e.
subclinical disease).
Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2.
It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
Other Names:
4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic Complete Response Rate After De-escalated CRT in HPV-positive and/or p16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC).
Time Frame: 6 to 14 weeks after the last patient is enrolled, or approximately 24 to 32 months after study being opened
|
Pathologic Complete Response Rate is defined as no evidence of residual viable cancer in the evaluated pathological specimens.
|
6 to 14 weeks after the last patient is enrolled, or approximately 24 to 32 months after study being opened
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Two-Year Local Control
Time Frame: Median follow-up was 36 months with a range of 5-53 months
|
Local control is the arrest of cancer growth at the site of origin.
|
Median follow-up was 36 months with a range of 5-53 months
|
Regional Control
Time Frame: Median follow-up was 36 months with a range of 5-53 months
|
Regional control is the percentage of participants who displayed control of cancer in sites that represent the first stages of spread from the local origin.
|
Median follow-up was 36 months with a range of 5-53 months
|
Cause-Specific Survival
Time Frame: The median follow-up was 36 months with a range of 5-53 months
|
Cause-specific survival is the percentage of participants who have not died from low-risk low-risk OPSCC.
|
The median follow-up was 36 months with a range of 5-53 months
|
Distant Metastases Free Survival
Time Frame: the median follow-up was 36 months with a range of
|
Distant metastases free survival is the percentage of subjects in a study who have survived without cancer spread.
|
the median follow-up was 36 months with a range of
|
Overall Survival Rate
Time Frame: Median follow-up was 36 months with a range of 5-53 months.
|
The percentage of participants who are still alive from the start of treatment.
|
Median follow-up was 36 months with a range of 5-53 months.
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-H&N-35
Time Frame: Prior to CRT, 4-8 weeks after CRT, follow-up visits for 2 years after CRT
|
The head & neck cancer module of the EORTC QLQ comprises 35 questions assessing symptoms and side effects of treatment, social function and body image/sexuality. The head & neck cancer module incorporates seven multi-item scales that assess pain, swallowing, senses (taste and smell), speech, social eating, social contact and sexuality. There are also eleven single items. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'); several single item questions (Pain killers, nutritional supplements, feeding tube, weight loss, and weight gain) were just coded as no=1, yes=2. The scores of these scales were averaged from the scores of the component items, transformed and analyzed on a 0 - 100 scale. For all items and scales, high scores indicate more problems (i.e. there are no function scales in which high scores would mean better functioning). |
Prior to CRT, 4-8 weeks after CRT, follow-up visits for 2 years after CRT
|
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status/QoL
Time Frame: Prior to CRT, 4-8 weeks after CRT, follow-up visits for 2 years after CRT
|
The EORTC QLQ-C30 is a cancer-specific instrument with 30 questions which incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale.
Most questions used 4 point scale (1 'Not at all' to 4 'Very much'); 2 questions used 7-point scale (1 'very poor' to 7 'Excellent').
The scores of these scales were averaged from the scores of the component items, transformed and analyzed on a 0 - 100 scale.
A higher score=better level of functioning or greater degree of symptoms.
|
Prior to CRT, 4-8 weeks after CRT, follow-up visits for 2 years after CRT
|
The Eating Assessment Tool (EAT-10) Composite Score
Time Frame: Prior to CRT, 4-8 weeks after CRT, follow-up visits for 2 years after CRT
|
The EAT-10 is a 10 item, validated self-administered instrument for documenting dysphagia severity.
This questionnaire uses symptom-specific scores to assess dysphasia with solids, liquids, and pills as well as the impact of dysphagia on mental, social, and physical health.
Higher raw scores represent worse QoL.
All items have a 0-4 scale where 0 represents no problem and 4 represents severe problem.
Total score can range from 0 to 40.
|
Prior to CRT, 4-8 weeks after CRT, follow-up visits for 2 years after CRT
|
The Rosenbek Penetration Aspiration Scale
Time Frame: Prior to CRT and 4-8 weeks after completion of CRT
|
The Rosenbek Penetration Aspiration Scale will be used to quantify dysphagia. It is an 8-point, equal-appearing interval scale to describe penetration and aspiration events. The measure was used for thin substances, pureed substances, and solid substances. 1. Material does not enter airway 2. Material enters the airway, remains above the vocal folds, and is ejected from the airway. 3. Material enters the airway, remains above the vocal folds, and is not ejected from the airway. 4. Material enters the airway, contacts the vocal folds, and is ejected from the airway. 5. Material enters the airway, contacts the vocal folds, and is not ejected from the airway. 6.Material enters the airway, passes below the vocal folds, and is ejected into the larynx or out of the airway. 7. Material enters the airway, passes below the vocal folds, and is not ejected from the trachea despite effort. 8. Material enters the airway, passes below the vocal folds, and no effort is made to eject. |
Prior to CRT and 4-8 weeks after completion of CRT
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.
- Mavroidis P, Price A, Fried D, Kostich M, Amdur R, Mendenhall W, Liu C, Das S, Marks LB, Chera B. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer. Radiother Oncol. 2017 Aug;124(2):240-247. doi: 10.1016/j.radonc.2017.06.020. Epub 2017 Jul 13.
- Chera BS, Amdur RJ, Tepper J, Qaqish B, Green R, Aumer SL, Hayes N, Weiss J, Grilley-Olson J, Zanation A, Hackman T, Funkhouser W, Sheets N, Weissler M, Mendenhall W. Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):976-85. doi: 10.1016/j.ijrobp.2015.08.033. Epub 2015 Aug 22.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Neoplasms, Squamous Cell
- Neoplasms
- Head and Neck Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Oropharyngeal Neoplasms
- Antineoplastic Agents
- Cisplatin
Other Study ID Numbers
- LCCC 1120
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
AZ Sint-Jan AVRecruiting
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Jonsson Comprehensive Cancer CenterWithdrawnHead and Neck CarcinomaUnited States
Clinical Trials on Intensity Modulated Radiotherapy (IMRT)
-
New Mexico Cancer Care AllianceCompletedNeoplasm Metastasis | Central Nervous System MetastasesUnited States
-
University College, LondonCancer Research UK; NCRI Radiotherapy Trials QA (RTTQA) GroupCompletedEwing Sarcoma | Chordoma | Bone Sarcoma | Soft Tissue Sarcoma, AdultUnited Kingdom, Ireland
-
M.D. Anderson Cancer CenterUnknownProstate CancerUnited States
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
Institut Claudius RegaudWithdrawn
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompleted
-
The Central Hospital of Lishui CityNot yet recruitingEsophageal Squamous Cell Carcinoma by AJCC V8 Stage
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedNeoplasm MetastasisUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingMelanoma | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Esthesioneuroblastoma | Squamous Cell Carcinoma | Sinonasal Carcinoma | Myoepithelial Carcinoma | Sinonasal Undifferentiated Carcinoma | Schneiderian CarcinomaUnited States
-
Jun-Lin Yi, MDRecruiting